These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 32151496)
1. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky. Stone J; Fraser H; Young AM; Havens JR; Vickerman P Int J Drug Policy; 2021 Feb; 88():102707. PubMed ID: 32151496 [TBL] [Abstract][Full Text] [Related]
2. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600 [TBL] [Abstract][Full Text] [Related]
3. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207 [TBL] [Abstract][Full Text] [Related]
4. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449 [TBL] [Abstract][Full Text] [Related]
5. Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study. Stone J; Lim AG; Dore GJ; Borquez A; Geddes L; Gray R; Grebely J; Hajarizadeh B; Iversen J; Maher L; Valerio H; Martin NK; Hickman M; Lloyd AR; Vickerman P Liver Int; 2023 Mar; 43(3):569-579. PubMed ID: 36305315 [TBL] [Abstract][Full Text] [Related]
6. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M Addiction; 2018 Mar; 113(3):545-563. PubMed ID: 28891267 [TBL] [Abstract][Full Text] [Related]
7. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410 [TBL] [Abstract][Full Text] [Related]
8. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093 [TBL] [Abstract][Full Text] [Related]
9. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808 [TBL] [Abstract][Full Text] [Related]
10. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064 [TBL] [Abstract][Full Text] [Related]
11. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania. Fraser H; Stone J; Wisse E; Sambu V; Mfisi P; Duran IJ; Soriano MA; Walker JG; Makere N; Luhmann N; Kafura W; Nouvellet M; Ragi A; Mundia B; Vickerman P J Int AIDS Soc; 2021 Oct; 24(10):e25817. PubMed ID: 34661964 [TBL] [Abstract][Full Text] [Related]
12. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116 [TBL] [Abstract][Full Text] [Related]
14. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. MacArthur GJ; van Velzen E; Palmateer N; Kimber J; Pharris A; Hope V; Taylor A; Roy K; Aspinall E; Goldberg D; Rhodes T; Hedrich D; Salminen M; Hickman M; Hutchinson SJ Int J Drug Policy; 2014 Jan; 25(1):34-52. PubMed ID: 23973009 [TBL] [Abstract][Full Text] [Related]
15. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada. Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651 [TBL] [Abstract][Full Text] [Related]
16. Modelling the contribution of incarceration and public health oriented drug law reform to HCV transmission and elimination among PWID in Tijuana, Mexico. Saldana CDR; Beletsky L; Borquez A; Kiene SM; Marquez LK; Strathdee SA; Zúñiga ML; Cepeda J; Martin NK Int J Drug Policy; 2022 Dec; 110():103878. PubMed ID: 36242829 [TBL] [Abstract][Full Text] [Related]
17. Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets? Ward Z; Platt L; Sweeney S; Hope VD; Maher L; Hutchinson S; Palmateer N; Smith J; Craine N; Taylor A; Martin N; Ayres R; Dillon J; Hickman M; Vickerman P Addiction; 2018 May; 113(9):1727-38. PubMed ID: 29774607 [TBL] [Abstract][Full Text] [Related]
18. Modeling the impact of a supervised consumption site on HIV and HCV transmission among people who inject drugs in three counties in California, USA. Killion JA; Jegede OS; Werb D; Davidson PJ; Smith LR; Gaines T; Graff Zivin J; Zúñiga ML; Pines HA; Garfein RS; Strathdee SA; Rivera Saldana C; Martin NK Int J Drug Policy; 2024 Oct; 132():104557. PubMed ID: 39213827 [TBL] [Abstract][Full Text] [Related]
19. Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection. Artenie AA; Hickman M; Vickerman P; Stone J; Grebely J; Bruneau J Int J Drug Policy; 2021 Oct; 96():103419. PubMed ID: 34452807 [TBL] [Abstract][Full Text] [Related]
20. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Vickerman P; Martin N; Turner K; Hickman M Addiction; 2012 Nov; 107(11):1984-95. PubMed ID: 22564041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]